Form 8-K - Current report:
SEC Accession No. 0001837607-25-000010
Filing Date
2025-02-07
Accepted
2025-02-07 16:07:29
Documents
16
Period of Report
2025-02-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20250203x8k.htm   iXBRL 8-K 43670
2 EX-99 aeon-20250203xex99.htm EX-99 16471
3 GRAPHIC aeon-20250203xex99001.jpg GRAPHIC 3801
  Complete submission text file 0001837607-25-000010.txt   203566

Data Files

Seq Description Document Type Size
4 EX-101.SCH aeon-20250203.xsd EX-101.SCH 4041
5 EX-101.DEF aeon-20250203_def.xml EX-101.DEF 2866
6 EX-101.LAB aeon-20250203_lab.xml EX-101.LAB 17850
7 EX-101.PRE aeon-20250203_pre.xml EX-101.PRE 10672
18 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20250203x8k_htm.xml XML 5003
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 25601737
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)